Activist fans, another lite day. Activist news and stories below. Send tips to daily newsletter, and ICYMI the latest newsletter, it’s here.
- Trian Fund and Nelson Peltz has dumped some of its Legg Mason shares. It lowered its stake by 5% and still owns 10.88% of the company.
- Kyle Bass is still at it with pharma patent challenges. Today, it’s Jazz Pharmaceuticals and its narcolepsy drug Xyrem. Recall Bass also announced challenges against Shire this week.
- Elliott Management finally books a win, getting Informatica sold. it’s going private for $48.75 a share. Note that Elliott went active with an 8% stake back in Jan.
Voss Capital is betting on a housing market boom
The Voss Value Fund was up 4.09% net for the second quarter, while the Voss Value Offshore Fund was up 3.93%. The Russell 2000 returned 25.42%, the Russell 2000 Value returned 18.24%, and the S&P 500 gained 20.54%. In July, the funds did much better with a return of 15.25% for the Voss Value Fund Read More
- @activistinvestr puts together a piece on the PwC report about activist investors from a few week’s ago. The standout for The Activist Investor blog is the PwC tool for assessing the risk of being targeted by an activist. Takeaway, “Among other helpful items from PwC, including a full report and a video, the risk assessment tool piques our interest.” [link]
- @SharpeTrade lays out how activist investors can hurt and help the retail investor. Now it’s not the best-written piece, but bear with me. The focus is on Apple and to some extent IBM. I highlight this piece to outline how misunderstood activist investing is at times. The media and retail investors view activism in a bubble and apply it only to the stocks they care about. If you’re going to look at how activists hurt and help retail investors, you must do so on a broader spectrum, and one that’s a fair playing field [link]